加味乌梅丸防治溃疡性结肠炎的免疫调控机制研究
|
摘要
溃疡性结肠炎(Ulcerative Colitis,UC)是炎症性肠病(inflammatory boweldisease,IBD)的一种,以结肠溃疡形成为病理特征。近年来,在我国发病率逐年增高。本病确切的发病机制至今仍不清楚,认为是由多种因素相互作用所致,主要包括免疫、遗传、感染、及精神心理因素;其发病既有自身免疫机制的参与,也有遗传因素作为背景,感染和精神因素只是诱发因素。治疗方面,现代医学常用氨基水杨酸类和糖皮质激素类药物,但存在易复发和一定程度的不良反应。
中医将溃疡性结肠炎归属于“泄泻”、“痢疾”等范畴,中医认为溃疡性结肠炎患者病位在肠,多以脾胃虚弱为本,湿热毒邪为标,瘀血痰浊阻滞肠络的病理变化贯穿疾病始终,病程日久,累及脾肾,则可见脾肾虚弱。古代经典名方—乌梅丸主治病机与本证相符,临床多年用于治疗溃疡性结肠炎,疗效好、复发率低、不良反应少,具有良好的研究价值。加味乌梅丸是导师韩涛副教授依据临床经验,结合现代研究的科研成果,组成的科研处方。该中药复方经过多年临床验证,具有较好疗效,与单纯乌梅丸相比,紧扣病机,在功效上有较大的突破。
本论文复制溃疡性结肠炎大鼠模型,并对模型进行评价;观察加味乌梅丸对溃疡性结肠炎大鼠保护作用;在以往研究的基础上,选取与溃疡性结肠炎发病机理密切相关的血清IFN-γ、结肠组织iNOS、P-选择素、ICAM-1作为指标,运用ELISA、免疫组化等检测技术,从整体、组织、细胞、分子水平,深入研究加味乌梅丸对溃疡性结肠炎大鼠的免疫作用机理。主要研究内容如下:
1文献综述
上篇通过查阅、整理国内外溃疡性结肠炎的相关研究资料,从中医、西医两方面对溃疡性结肠炎进行系统的综述。
2研究内容
2.1处方研究
加味乌梅丸由《伤寒论》厥阴病篇中的乌梅丸化裁而成。根据中医理论对该处方进行分析,将其功效定位为涩肠止泻,健脾益气,调和寒热,活血止痛。该方可用于脾虚日久,寒热错杂,瘀血阻滞引起的腹痛,腹泻,里急后重,黏液脓血便。同时,通过研究处方中诸药的药理学进展,进一步全面分析该处方。
2.2加味乌梅丸对TNBS型溃疡性结肠炎大鼠治疗作用的研究
本研究复制TNBS/乙醇UC大鼠模型。随机分为正常组,模型组,柳氮磺胺吡啶组(SASP),加味乌梅丸低、中、高剂量组。从疾病活动指数(DAI)、结肠黏膜损伤指数(CMDI)、结肠黏膜镜下病理形态学等方面,对加味乌梅丸的疗效进行评价。结果发现,模型组DAI与正常组之间差异非常显著(P＜0.01);模型组和治疗组之间有显著性差异,SASP和加味乌梅丸均可使DAI降低(P＜0.05),尤以加味乌梅丸中剂量更明显(P＜0.01)。模型组的CMDI与正常组相比,差异非常显著(P＜0.01);模型组和治疗组之间有显著性差异(P＜0.01),其中SASP和加味乌梅丸可使CMDI明显降低(P＜0.01)。
以上结果表明,本实验的溃疡性结肠炎模型复制成功,加味乌梅丸对TNBS/乙醇所致的溃疡性结肠炎大鼠模型有良好的防治作用。
2.3加味乌梅丸对TNBS型溃疡性结肠炎大鼠的免疫机制的研究
2.3.1加味乌梅丸对溃疡性结肠炎大鼠模型结肠组织iNOS的影响
模型组iNOS阳性率明显增高,与正常组比较有显著差异(P＜0.01);加味乌梅丸各组和SASP组iNOS阳性率下降,与模型组比较,有显著差异(P＜0.05),以加味乌梅丸中剂量组下降最为明显(P＜0.01)。
2.3.2加味乌梅丸对溃疡性结肠炎大鼠模型结肠组织P-选择素的影响
模型组P-选择素阳性率明显增高,与正常组比较有显著差异(P＜0.01);加味乌梅丸各组和SASP组P-选择素阳性率下降,与模型组比较有显著差异(P＜0.05),尤以加味乌梅丸中剂量组下降最为明显(P＜0.01)。
2.3.3加味乌梅丸对溃疡性结肠炎大鼠模型结肠组织ICAM-1的影响
模型组ICAM-1阳性率明显增高,与正常组比较有显著差异(P＜0.01);加味乌梅丸各组和SASP组ICAM-1阳性率下降,与模型组比较有显著差异(P＜0.05),尤以加味乌梅丸中剂量组下降最为明显(P＜0.01)。
2.3.4加味乌梅丸对溃疡性结肠炎大鼠模型血清IFN-γ的影响
模型组IFN-γ阳性率明显增高,与正常组比较有显著差异(P＜0.01);加味乌梅丸高、中、低剂量组血清IFN-γ的水平下降,与模型组比较有显著差异(P＜0.05),尤以加味乌梅丸中剂量组下降最为明显(P＜0.01)。
2.3.5机理分析
实验结果提示,加味乌梅丸具有明显的抗溃疡性结肠炎的效果;分析其机理,可能是通过下调iNOS的表达阻止机体免疫防御系统的启动,使T、B、NK细胞等淋巴细胞的分化减弱,下调促炎细胞因子IFN-γ的表达,从而使中性粒细胞、NK细胞和血管内皮细胞等炎性细胞的活化和浸润减少,血小板活化减少。那么在结肠组织中,P-选择素不能介导白细胞的复始黏附,不能介导ICAM-1黏附、趋化、淋巴细胞归巢等作用,参与炎症和免疫反应。最终,导致肠黏膜的损伤减少,起到治疗溃疡性结肠炎的作用。通过本实验,也证实免疫因素在溃疡性结肠炎发病中的重要作用。上述免疫分子可能是加味乌梅丸防治溃疡性结肠炎的作用靶点。
3结论
脾虚为本,湿热为标是溃疡性结肠炎的主要病机;以涩肠止泻,益气健脾,调和寒热,活血止痛立法的加味乌梅丸能有效的控制炎症的启动。通过本实验,我们得出结论,加味乌梅丸对TNBS型溃疡性结肠炎大鼠有着良好的保护作用,其治疗效果尤其在改善机体免疫系统方面,显示出中医药在提高机体的免疫防御功能方面具有的巨大优势。它通过益气健脾提高机体的免疫功能,调和寒热阻止炎症的发生,避免发生免疫系统级联反应,最终达到治疗溃疡性结肠炎的目的。我们相信随着对溃疡性结肠炎发病机制的深入研究,加味乌梅丸对溃疡性结肠炎的治疗作用机理将会得到更全面,更深刻的阐释。
The ulcerative colitis is one of the inflammatory bowel disease,takes ulcer as pathology characteristic.In recent years,its incidence advanced year by year in our country. In spite of this sickness accurate pathogenesis is not clear until now,we thought that is interacted by many kinds of factor,mainly including immunity,heredity,infection,and stress disorder factor;Its morbidity already has own immunity mechanism participation,also has the hereditary factors to take the background.Obviously,infection and energetic factor only induces the factor.In treatment aspect,aminosalicylic acids and sugar cortical hormone medicine commonly were used in clinic,but exists easy to recur and untoward effect in the certain extent.
UC is relegated in "the diarrhea","dysentery" and so on in Chinese medicine,it revealed that the UC patient shortcoming is in the intestines,many take the weakness of spleen and stomach as the base,but wet hot is the sign,the stasis bloody sputum hinders the pathological change.These changes penetration disease which muddy the intestines wind,and it will implicate the spleen kidney at last,then the obvious spleen kidney is weak.Ancient classical prescription-WMW mainly treated the pathogenesis with this card match case.It used to treat UC in the clinical many years,and the curative effect are good.the recurrence rate low,the untoward effect were few,so the good research value is obvious.According to the theory of TCM,Jiawei Wumei Wan(JWW)which bases of clinical experience,and unites modern research achievements in scientific research,composes scientific research prescription.
We duplicates UC rat model,and carries on the appraisal to the model;observate JWW to UC rat protective function;select indexs which closely related UC pathogenesis:blood serum IFN-γ,the colon organizes iNOS,P-selection,ICAM-1,to take the target.Then we utilizes ELISA and Immunohistochemistry to deeply research JWW to immunity action mechanism of UC rat from the whole,the organization,the cell,the molecular level.The main research content is as follows:
1 Literature review
We had reviewed literatures about the general situation of UC from TCM and western medicine in domestic and abroad.
2 Research
2.1 Prescription research
JWW stems from "Treatise on Febrile diseases" jueyin disease.The demonstration of JWW that guided by TCM theories analysis:antidarrhea with astringent,invigorate the spleen and profit pneuma,reconcile chills and fever,promote blood circulation to arrest pain.This will use in spleen weakness in the course of time,the cold-heat jumble,and ecchymosis will hinder the abdominal pain which will cause the diarrhea,the tenesmus,the mucus pus bloody stool.At the same time,through researching pharmacology progress in prescription,further overall is analysised this prescription.
2.2 The research on treat UC/TNBS rat through JWW
This research duplicates TNBS/alcohol UC rat model.Divided into the normal group,the model group,sulfasalazine enteric-coated tablets(SASP)group,JWW high-dose, middle-dose,low-dose group stochastically.From disease activity index(DAI),colon mucous membrane damage index(CMDI),the colon mucous membrane the pathology morphology on light microscope aspect,we appraise JWW curative effect.The result discovered that DAI between model group and normal group the difference is remarkable(P＜0.01);Between the model group and the treated group has the significance difference,SASP and JWW both possibly cause DAI to redUCe(P＜0.05).Especially,JWW middle-dose group is more dramatic(P＜0.01).Compared with normal group,model group's CMDI on light microscope elevates obviously(P＜0.01);Between the model group and the treated group,it has the significance difference(P＜0.01),SASP and JWW cause CMDI to reduce obviously (P＜0.01).
The above result indicated that this experiment's UC model duplicates successfully.JWW to TNBS/alcohol UC rat has obvious prevention function.
2.3The research of immunologic mechanism about JWW for TNBS/UC rat
2.3.1 The influence about JWW for UC rat colon tissue iNOS
The masc rate of colon tissue iNOS was clearly raised up in the model group,compared with the normal group(P＜0.01).While in the three-dose JWW groups and SASP group,the masc rate of colon tissue iNOS was dramaticly descended,compared with the model group(P＜0.05),especially the middle-dose JWW group(P＜0.01).
2.3.2 The influence about JWW for UC rat colon tissue P-selectin
The masc rate of colon tissue P-selectin was clearly raised up in the model group,compared with the normal 1 group(P＜0.01).While in the three-dose JWW groups and SASP group,masc rate of the colon tissue P-selectin was dramaticly descended,compared with the model group(P＜0.05),especially the middle-dose JWW group(P＜0.01).
2.3.3The influence about JWW for UC rat colon tissue ICAM-1
The masc rate of colon tissue ICAM-1 was clearly raised up in the model group,compared with the normal group(P＜0.01).While in the three-dose JWW groups and SASP group,the masc rate of colon tissue ICAM-1 was dramaticly descended,compared with the model group(P＜0.05),especially the middle-dose JWW group(P＜0.01).
2.3.4 The influence about JWW for UC rat serum IFN-γ
The masc rate of serum IFN-γwas clearly raised up in the model group,compared with the normal group(P＜0.01).While the high,middle and low-dose JWW group,the level of serum IFN-γ,was dramaticly descended,compared with the model group(P＜0.05).
2.3.5 Mechanism analysis
The experimental result indicates,JWW has obvious anti-UC effect;analyzing its mechanism:possibly first declining iNOS expression to prevent organism immune defense system,cause lymphocyte and T,B,NK cell differentiations to weaken,decline IFN-γexpression,thus causes the polymorphonuclear neutrophil,NK cell and the blood vessel endothelial cell's activation and infiltration to reduce,blood platelet activation is reduced. Therefore,the P-selectin cannot mediate the white blood cell to adheres and accumulation; cannot mediate the ICAM-1 to adhere,hasten,and the lymphocyte to turn over nesting,participate inflammation and immune response.Finally,the intestines mucous membrane damage is reduced and ulcerous colitis is treated.Through the experiment, immunity factor was confirmed to influential role once more in the UC morbidity.The target which JWW could treat UC possibly relates with the above immune molecule.
3 Conclusion
UC main pathogenesis is based of spleen weakness and signed of hot and damp; Throught antidarrhea with astringent,invigorate the spleen and profit pneuma,reconcile chills and fever,promoting blood circulation to arrest pain,JWW can control inflammation starting effectly.According to this experimental study,we conclude that JWW could pretect TNBS/UC rat.Treatment is better in improvement organism immune system.It demonstrated TCM have huge superiority in enhancing organism immune defense function aspect, moreover,not poisonous side effect comparing with western medicine.JWW is good for the spleen through nourishing qi,enhances organism immunologic function;well distributed cold and heat could prevent inflammation's occurrence and avoids having immune system cascade respond,thus achieves to treat UC.
中医将溃疡性结肠炎归属于“泄泻”、“痢疾”等范畴,中医认为溃疡性结肠炎患者病位在肠,多以脾胃虚弱为本,湿热毒邪为标,瘀血痰浊阻滞肠络的病理变化贯穿疾病始终,病程日久,累及脾肾,则可见脾肾虚弱。古代经典名方—乌梅丸主治病机与本证相符,临床多年用于治疗溃疡性结肠炎,疗效好、复发率低、不良反应少,具有良好的研究价值。加味乌梅丸是导师韩涛副教授依据临床经验,结合现代研究的科研成果,组成的科研处方。该中药复方经过多年临床验证,具有较好疗效,与单纯乌梅丸相比,紧扣病机,在功效上有较大的突破。
本论文复制溃疡性结肠炎大鼠模型,并对模型进行评价;观察加味乌梅丸对溃疡性结肠炎大鼠保护作用;在以往研究的基础上,选取与溃疡性结肠炎发病机理密切相关的血清IFN-γ、结肠组织iNOS、P-选择素、ICAM-1作为指标,运用ELISA、免疫组化等检测技术,从整体、组织、细胞、分子水平,深入研究加味乌梅丸对溃疡性结肠炎大鼠的免疫作用机理。主要研究内容如下:
1文献综述
上篇通过查阅、整理国内外溃疡性结肠炎的相关研究资料,从中医、西医两方面对溃疡性结肠炎进行系统的综述。
2研究内容
2.1处方研究
加味乌梅丸由《伤寒论》厥阴病篇中的乌梅丸化裁而成。根据中医理论对该处方进行分析,将其功效定位为涩肠止泻,健脾益气,调和寒热,活血止痛。该方可用于脾虚日久,寒热错杂,瘀血阻滞引起的腹痛,腹泻,里急后重,黏液脓血便。同时,通过研究处方中诸药的药理学进展,进一步全面分析该处方。
2.2加味乌梅丸对TNBS型溃疡性结肠炎大鼠治疗作用的研究
本研究复制TNBS/乙醇UC大鼠模型。随机分为正常组,模型组,柳氮磺胺吡啶组(SASP),加味乌梅丸低、中、高剂量组。从疾病活动指数(DAI)、结肠黏膜损伤指数(CMDI)、结肠黏膜镜下病理形态学等方面,对加味乌梅丸的疗效进行评价。结果发现,模型组DAI与正常组之间差异非常显著(P＜0.01);模型组和治疗组之间有显著性差异,SASP和加味乌梅丸均可使DAI降低(P＜0.05),尤以加味乌梅丸中剂量更明显(P＜0.01)。模型组的CMDI与正常组相比,差异非常显著(P＜0.01);模型组和治疗组之间有显著性差异(P＜0.01),其中SASP和加味乌梅丸可使CMDI明显降低(P＜0.01)。
以上结果表明,本实验的溃疡性结肠炎模型复制成功,加味乌梅丸对TNBS/乙醇所致的溃疡性结肠炎大鼠模型有良好的防治作用。
2.3加味乌梅丸对TNBS型溃疡性结肠炎大鼠的免疫机制的研究
2.3.1加味乌梅丸对溃疡性结肠炎大鼠模型结肠组织iNOS的影响
模型组iNOS阳性率明显增高,与正常组比较有显著差异(P＜0.01);加味乌梅丸各组和SASP组iNOS阳性率下降,与模型组比较,有显著差异(P＜0.05),以加味乌梅丸中剂量组下降最为明显(P＜0.01)。
2.3.2加味乌梅丸对溃疡性结肠炎大鼠模型结肠组织P-选择素的影响
模型组P-选择素阳性率明显增高,与正常组比较有显著差异(P＜0.01);加味乌梅丸各组和SASP组P-选择素阳性率下降,与模型组比较有显著差异(P＜0.05),尤以加味乌梅丸中剂量组下降最为明显(P＜0.01)。
2.3.3加味乌梅丸对溃疡性结肠炎大鼠模型结肠组织ICAM-1的影响
模型组ICAM-1阳性率明显增高,与正常组比较有显著差异(P＜0.01);加味乌梅丸各组和SASP组ICAM-1阳性率下降,与模型组比较有显著差异(P＜0.05),尤以加味乌梅丸中剂量组下降最为明显(P＜0.01)。
2.3.4加味乌梅丸对溃疡性结肠炎大鼠模型血清IFN-γ的影响
模型组IFN-γ阳性率明显增高,与正常组比较有显著差异(P＜0.01);加味乌梅丸高、中、低剂量组血清IFN-γ的水平下降,与模型组比较有显著差异(P＜0.05),尤以加味乌梅丸中剂量组下降最为明显(P＜0.01)。
2.3.5机理分析
实验结果提示,加味乌梅丸具有明显的抗溃疡性结肠炎的效果;分析其机理,可能是通过下调iNOS的表达阻止机体免疫防御系统的启动,使T、B、NK细胞等淋巴细胞的分化减弱,下调促炎细胞因子IFN-γ的表达,从而使中性粒细胞、NK细胞和血管内皮细胞等炎性细胞的活化和浸润减少,血小板活化减少。那么在结肠组织中,P-选择素不能介导白细胞的复始黏附,不能介导ICAM-1黏附、趋化、淋巴细胞归巢等作用,参与炎症和免疫反应。最终,导致肠黏膜的损伤减少,起到治疗溃疡性结肠炎的作用。通过本实验,也证实免疫因素在溃疡性结肠炎发病中的重要作用。上述免疫分子可能是加味乌梅丸防治溃疡性结肠炎的作用靶点。
3结论
脾虚为本,湿热为标是溃疡性结肠炎的主要病机;以涩肠止泻,益气健脾,调和寒热,活血止痛立法的加味乌梅丸能有效的控制炎症的启动。通过本实验,我们得出结论,加味乌梅丸对TNBS型溃疡性结肠炎大鼠有着良好的保护作用,其治疗效果尤其在改善机体免疫系统方面,显示出中医药在提高机体的免疫防御功能方面具有的巨大优势。它通过益气健脾提高机体的免疫功能,调和寒热阻止炎症的发生,避免发生免疫系统级联反应,最终达到治疗溃疡性结肠炎的目的。我们相信随着对溃疡性结肠炎发病机制的深入研究,加味乌梅丸对溃疡性结肠炎的治疗作用机理将会得到更全面,更深刻的阐释。
The ulcerative colitis is one of the inflammatory bowel disease,takes ulcer as pathology characteristic.In recent years,its incidence advanced year by year in our country. In spite of this sickness accurate pathogenesis is not clear until now,we thought that is interacted by many kinds of factor,mainly including immunity,heredity,infection,and stress disorder factor;Its morbidity already has own immunity mechanism participation,also has the hereditary factors to take the background.Obviously,infection and energetic factor only induces the factor.In treatment aspect,aminosalicylic acids and sugar cortical hormone medicine commonly were used in clinic,but exists easy to recur and untoward effect in the certain extent.
UC is relegated in "the diarrhea","dysentery" and so on in Chinese medicine,it revealed that the UC patient shortcoming is in the intestines,many take the weakness of spleen and stomach as the base,but wet hot is the sign,the stasis bloody sputum hinders the pathological change.These changes penetration disease which muddy the intestines wind,and it will implicate the spleen kidney at last,then the obvious spleen kidney is weak.Ancient classical prescription-WMW mainly treated the pathogenesis with this card match case.It used to treat UC in the clinical many years,and the curative effect are good.the recurrence rate low,the untoward effect were few,so the good research value is obvious.According to the theory of TCM,Jiawei Wumei Wan(JWW)which bases of clinical experience,and unites modern research achievements in scientific research,composes scientific research prescription.
We duplicates UC rat model,and carries on the appraisal to the model;observate JWW to UC rat protective function;select indexs which closely related UC pathogenesis:blood serum IFN-γ,the colon organizes iNOS,P-selection,ICAM-1,to take the target.Then we utilizes ELISA and Immunohistochemistry to deeply research JWW to immunity action mechanism of UC rat from the whole,the organization,the cell,the molecular level.The main research content is as follows:
1 Literature review
We had reviewed literatures about the general situation of UC from TCM and western medicine in domestic and abroad.
2 Research
2.1 Prescription research
JWW stems from "Treatise on Febrile diseases" jueyin disease.The demonstration of JWW that guided by TCM theories analysis:antidarrhea with astringent,invigorate the spleen and profit pneuma,reconcile chills and fever,promote blood circulation to arrest pain.This will use in spleen weakness in the course of time,the cold-heat jumble,and ecchymosis will hinder the abdominal pain which will cause the diarrhea,the tenesmus,the mucus pus bloody stool.At the same time,through researching pharmacology progress in prescription,further overall is analysised this prescription.
2.2 The research on treat UC/TNBS rat through JWW
This research duplicates TNBS/alcohol UC rat model.Divided into the normal group,the model group,sulfasalazine enteric-coated tablets(SASP)group,JWW high-dose, middle-dose,low-dose group stochastically.From disease activity index(DAI),colon mucous membrane damage index(CMDI),the colon mucous membrane the pathology morphology on light microscope aspect,we appraise JWW curative effect.The result discovered that DAI between model group and normal group the difference is remarkable(P＜0.01);Between the model group and the treated group has the significance difference,SASP and JWW both possibly cause DAI to redUCe(P＜0.05).Especially,JWW middle-dose group is more dramatic(P＜0.01).Compared with normal group,model group's CMDI on light microscope elevates obviously(P＜0.01);Between the model group and the treated group,it has the significance difference(P＜0.01),SASP and JWW cause CMDI to reduce obviously (P＜0.01).
The above result indicated that this experiment's UC model duplicates successfully.JWW to TNBS/alcohol UC rat has obvious prevention function.
2.3The research of immunologic mechanism about JWW for TNBS/UC rat
2.3.1 The influence about JWW for UC rat colon tissue iNOS
The masc rate of colon tissue iNOS was clearly raised up in the model group,compared with the normal group(P＜0.01).While in the three-dose JWW groups and SASP group,the masc rate of colon tissue iNOS was dramaticly descended,compared with the model group(P＜0.05),especially the middle-dose JWW group(P＜0.01).
2.3.2 The influence about JWW for UC rat colon tissue P-selectin
The masc rate of colon tissue P-selectin was clearly raised up in the model group,compared with the normal 1 group(P＜0.01).While in the three-dose JWW groups and SASP group,masc rate of the colon tissue P-selectin was dramaticly descended,compared with the model group(P＜0.05),especially the middle-dose JWW group(P＜0.01).
2.3.3The influence about JWW for UC rat colon tissue ICAM-1
The masc rate of colon tissue ICAM-1 was clearly raised up in the model group,compared with the normal group(P＜0.01).While in the three-dose JWW groups and SASP group,the masc rate of colon tissue ICAM-1 was dramaticly descended,compared with the model group(P＜0.05),especially the middle-dose JWW group(P＜0.01).
2.3.4 The influence about JWW for UC rat serum IFN-γ
The masc rate of serum IFN-γwas clearly raised up in the model group,compared with the normal group(P＜0.01).While the high,middle and low-dose JWW group,the level of serum IFN-γ,was dramaticly descended,compared with the model group(P＜0.05).
2.3.5 Mechanism analysis
The experimental result indicates,JWW has obvious anti-UC effect;analyzing its mechanism:possibly first declining iNOS expression to prevent organism immune defense system,cause lymphocyte and T,B,NK cell differentiations to weaken,decline IFN-γexpression,thus causes the polymorphonuclear neutrophil,NK cell and the blood vessel endothelial cell's activation and infiltration to reduce,blood platelet activation is reduced. Therefore,the P-selectin cannot mediate the white blood cell to adheres and accumulation; cannot mediate the ICAM-1 to adhere,hasten,and the lymphocyte to turn over nesting,participate inflammation and immune response.Finally,the intestines mucous membrane damage is reduced and ulcerous colitis is treated.Through the experiment, immunity factor was confirmed to influential role once more in the UC morbidity.The target which JWW could treat UC possibly relates with the above immune molecule.
3 Conclusion
UC main pathogenesis is based of spleen weakness and signed of hot and damp; Throught antidarrhea with astringent,invigorate the spleen and profit pneuma,reconcile chills and fever,promoting blood circulation to arrest pain,JWW can control inflammation starting effectly.According to this experimental study,we conclude that JWW could pretect TNBS/UC rat.Treatment is better in improvement organism immune system.It demonstrated TCM have huge superiority in enhancing organism immune defense function aspect, moreover,not poisonous side effect comparing with western medicine.JWW is good for the spleen through nourishing qi,enhances organism immunologic function;well distributed cold and heat could prevent inflammation's occurrence and avoids having immune system cascade respond,thus achieves to treat UC.
引文
[1]王吉耀,廖二元,胡品津.内科学[M].北京:人民卫生出版社,2005
[2]梁英杰.炎症性肠病溃疡性结肠炎和克隆病[J].广东医学,2001,22(11):984-985
[3]李亚红,韩英,吴开春.炎症性肠病危险因素的流行病学调查研究[J].胃肠病学和肝病学杂志.2006,15(2):161-162
[4]艾中立,钱群.溃疡性结肠炎的发病机理及临床特点[J].大肠肛门病外科杂志,2004,10(2):92-94
[5]王丽.溃疡性结肠炎病因及中医证治浅析[J].中医药学刊,2004,2(12):2278-2279
[6]肖梅,吴正祥.炎症性肠病的病因研究进展[J].安徽医药,2005,9(12):886-889
[7]施茵,吴焕淦,汪崇淼,等.针药结合对溃疡性结肠炎大鼠结肠粘膜IFN-γ,IL-12表达的影响[J].针刺研究,2005,30(4):215-219
[8]许尚栋,唐福林.γ-干扰素及其在类风湿关节炎中的应用[J].新医学,1995,26(6):329
[9]Carol M,Lambrechts A,Van GosumA,et al.Scretion of interferon-γ,and interleukin-4 by human intrae pithelial and lamina propriagut lymphocytes[J].Gut,1998,42(5):643
[10]Tozawa K,Hanai H,Sugimoto K,e tal.Evidence for the critical role of interleukin-12 but not interferon gam ma in the pathogenesis of experimental colitis in mice[J].Gas-troente rol Hepatol,2003,18:578
[11]MacDonald TT,Monteleone G,Pender SL.Resent development in the immunology of inflammatory bowel disease[J].ScandJ Immunol,2000,51(1):2
[12]针药结合对溃疡性结肠炎大鼠结肠粘膜IFN-γ,IL-12表达的影响[J].针灸研究,2005,30(4):215-224
[13]Schurmann GM,Bishop AE,Facer Pet al[J].Gut,1995,36(7):411-418
[14]Ohtani H,Nakamura S,Watanabe Yet al.Virchows Arch[A],1992,420(5):403-409
[15]Muller WA et al[J].Exp Med,1993,178(2):449-460
[16]Misra L,Misra BB,Harris M et al[J].Gastroenterology,1993,104(3):772-779
[17]李志晋,詹丽英,马春曦,等.溃疡性结肠炎大鼠肠黏膜超微结构变化及肠组织中P-选择素表达的研究[J].广西医科大学学报,2007,24(2):183-185
[18]Fagerstam J P,Whiss PA,Strom M,et al.Expression ofplatelet P-selection and detection of soluble P-selection,N YP and RANTES in patient with inflammatory bowel disease[J].Inflamm Res,2000,49(9):466-472.
[19]Vainer B,Nielsen OH.Changed colonic profile of P-selectin,platelet endothelial cell adhesion molecule-1(PEICAM-1),intercellular adhesi molecule-1(ICAM-1),ICAM-2,and ICAM-3 in inflammatory bowel disease[J].Clin Exp Immunol,2000,121(2):242-247.
[20]章荣华.炎症性肠病的免疫学研究进展[M].国外医学·免疫学分册,2000,23(1):57-59
[21]Mcever RP.In:Beckerle Me.Cell Adhesion[M],Oxford:Oxford University Press,2001,30
[22]周同,汤雪明.医学细胞生物学[M].北京:科学出版社,2004,226
[23]宋巍等.生命科学[M],2001,13:82
[24]SethR,Raymond FD,Makgoba MW.Circulating ICAM-1 isoforms:diagnostic prospects for inflammatory and immune disorders[J].Lancet,1991,338:83-89
[25]闫萍,乐进秋,江汉.细胞黏附分子ICAM-1在慢性牙周炎牙龈组织中白细胞的表达[J].广东牙病防治,2003,11(1):18-19.
[26]施茵,刘慧荣,龚烨靓,等,针药结合对大鼠溃疡性结肠炎TNF-α、ICAM-1基因表达的影响[J].实用中西医结合临床,2003,3(5):1-3.
[27]牛凤丽,郑萍,刘文忠,等.葡聚糖硫酸钠诱导大鼠结肠炎发病机制的研究[J].胃肠病学,2003,8(5):283-286.
[28]Bendjelloul F,Rossmann P,Maly P,et al.Detection of ICAM-1 deficient and wild type mice:animmunohistochemicalstudy[J].Histochem J,2000,32:703-709.
[29]Bendi jelloulF,Maly P,Mandys V,et al.Intercellular adhesion molecule-1(ICAM-1)deficiency protects mice against severe forms of experimentally induced colitis[J].Clin Explmmunol,2000,119:57-63.
[30]MaliziaG,CalabreseA,Cottone Metal[J].Gastroenterology,1991,100(1):150-156
[31]Pooley N,Ghosh L,Sharon P.Dig Dis Sci,1995,40(1):219-225
[32]Nielsen OH,Brynskov J,Vainer B,Dig Dis Sci,1996,41(9):1780-1785
[33]TaniguchiT.Effects of the anti-ICAM-1 monoclonal antibody on dextran sodium salphat e-induced colitis in rats[J].Gastroenterol Hepatol,1998,13(9):945-949
[34]Heuschkel RB.New immunologic treatments for inflammatory bowel disease[J].Curr Opin Gastroenterol,2000,16:565-570
[35]Wallace JL,Vergnolle N,Muscar MN,et al.Enhanced anti-inflammatory effects of anitric oxide releasing derivative of mesalamin in rats[J].Gastroenterology,1999,117:557-567
[36]姜恩平,孙红霞,曲娴,等.2,4,二硝基氯苯诱导的大鼠溃疡性结肠炎iNOS表达增加[J].北华大学学报(自然科学版),2006,7(2):121-124
[37]Boughen-amith NK,Evans SM,Hawkey CJ,et al.Nitric Oxide Synthase Activity in Ulcerative Colitis and Crohn' S Disease[J].Lanet,1993,342(86):338-340.
[38]Mourelle M.Expression of Inducible Nitric Oxide Synthase Activity in Human Colon Epithelial Ceil:Modulation by Tlymphocyte Derived Cytokines[J].Gut,1998,43(1):56-63.
[39]Dikopoulos N,Nussler AK,Liptay S,et al.Inhibition of nitric oxide synthesis by aminoguanidine increases intestinal damage in the acute phase of rat TNBS-colitis[J].Eur J Olin Invest,2001,31(3):234-239.
[40]Salas A,Gironella M,Salas A,et al.Nitric oxide supplementation ameliorates dextransulfate sodium-induced colitis in mice[J].Lab Invest,2002,82(5):597-607.
[41]Takahashi A,Tomomasa T,Kaneko H,et al.Intestinal motility in an in vivo rat model of intestinal ischemia-reperfusion with special reference to the effects of nitric oxide on the motility changes[J].Pediatr Gastroenterol Nutr,2001,33(3):283-288.
[42]Potoka DA,Nadler EP,Upperman JS,et al.Role of nitric oxide and peroxynitrite in gut barrier failure[J].World J Surg,2002,26(7):806-811.
[43]Cross RK,Wilson KT.Nitric oxide in inflammatory bowel disease[J].Inflamm Bowel Dis,2003,9(3):179-189.
[44]Rumi G,Tsubouchi R,Nishio H,et al.Dual role of endogenous nitric oxide indevelopment of dextran sodium sulfate-induced colitis in rats[J].Physiol Pharmacol,2004,55(4):823-836
[45]白爱平,沈志祥.一氧化氮与结肠炎模型急性期损伤[J].世界华人消化杂志,19997(10):900-901
[46]OudferF P,Bouma G,Visser TT,et al.Serum nitrate level in ulcerative colitis and Crohr disease[J].Scand J Gastroenterol,1995;30:784-788
[47]McCafferty DM,Mudgett JS,Swain MG,et al.Inducible nitric oxide synthase plays a critical role in resolving intestinal inflammation[J].Gastroenterology,1997,112(3):1022-1027
[48]Mc Cafferty DM,et al.Roie of Inducible nitric oxide synthase in trinitrobenzene sulph -onic acid induced colitis in mice[J].Gut,1999,45(6):864-873
[49]Ueyama H,et al[J].Gut,1998,43(1):48-55
[50]郑萍,陈胜良,莫剑忠,等.炎症性肠病患者T淋巴细胞亚群的改变及临床意义[J].胃肠病学,2000,5(4):221
[51]刑同京,章廉.Th类细胞极化群体的基础与临床[M].北京:军事医学科学技术出版社.2002:61
[52]余保平,王伟岸.消化系统疾病免疫学[M].北京:科学出版社.2000:189
[53]张涛.清肠栓对UC模型大鼠结肠黏膜固有层淋巴细胞Fas、FasL蛋白表达的影响[J],江苏中医药,2007,39(8):74-76.
[54]中华医学会消化病学分会.对炎症性肠病诊断治疗规范的建议2000年[J].现代实用医学,2003,15(10):656-659
[55]Hirohata S,Ohshima N,Yanagida T,et al.Regulation of human B cell function by sulfasalazine and its metabolites[J].Int Immunopharm acol,2002,2(5):631-641
[56]王雪梅,刘玉兰.环胞菌素A治疗溃疡性结肠炎的临床分析[J].中国内镜杂志,2003,9(11):16-17.
[1]李胜志,王大敏,李冀.中医对溃疡性结肠炎UC认识探源[J].中医药学刊,2003,21(9):1450-1451
[2]张苏颖,李淑云.溃疡性结肠炎中医辨治浅析[J].山东中医杂志,2003,22(10):579-581
[3]谭丹.溃疡性结肠炎的辨证分型治疗浅析[J].中医药学刊,2001,19(6):555
[4]周丽英,王长禄.辨证治疗慢性非特异性溃疡性结肠炎45例[J].国医论坛,2003,18(1):28
[5]金纯.中医对溃疡性结肠炎的认识与治疗[J].浙江中西医结合杂志,2002,12(11):688-689.
[6]张燕,刘鑫.溃疡性结肠炎的辨治思路及方法[J].安徽中医学院学报,2003,22(2):29-30
[7]白德臣,林才志,李桂贤,等.中医药治疗溃疡性结肠炎的进展[J].河南中医2005,25(10):83-85
[8]田海河.董建华教授治疗溃疡性结肠炎的经验[J].北京中医学院学报,1991,14(1):23
[9]王宝为.中药辨治非特异性溃疡性结肠炎45例[J].辽宁中医杂志,1999,26(2):66
[10]陆一春.慢性非特异型结肠炎分型论治3则[J].安徽中医学院学报,1998,(2):90
[11]赵明亮.中医药治疗慢性非特异性溃疡性结肠炎96例临床分析[J].中医杂志1993,(5):237
[12]高亚陇,高荣进.辨证分型治疗溃疡性结肠炎50例[J].陕西中医,1998,19(3):11
[13]李万铮.辨证治疗慢性结肠炎体会[J].四川中医,1999,17(6):13
[14]傅南琳,黄俊友.中医药治疗溃疡性结肠炎研究进展[J].中医杂志,1999,40,8:501
[15]曹众毅,邬建平.平衡中焦法治疗溃疡性结肠炎的体会[J]。中国医药学报,2003,18(10):617
[16]李泽生.中药治疗溃疡性结肠炎271例[J].中华中西医杂志,2003,4(4):572
[17]税典奎,刘宏伟.中西医结合治疗溃疡性结肠炎的临床观察[J].临沂医学专科学校学报,2002,4(24):300-301
[18]张晓梅,肖培新.以寒热为纲辩治溃疡性结肠炎[J].陕西中医函授,1998,6:7-8
[19]张传儒.调肝理脾法治疗慢性非特异性结肠炎30例报告[J].中医杂志,1990,31(8):36-37
[20]田凤鸣,刘玺珍.中医药治疗慢性非特异性溃疡性结肠炎的近况[J].北京中医杂志,1984,4:38-40.
[21]白丽萍,刘西峰.当归和血汤治疗溃疡性结肠炎30例[J].陕西中医,2004,25(9):796
[22]陈良金.健脾清肠汤治疗慢性溃疡性结肠炎62例[J].四川中医,2004,22(10):57
[23]卞耀臣,李振武.温里化痰法治疗慢性溃疡性结肠炎60例[J].山东中医杂志,2004,23(8):472
[24]张磊,李利霞,王梅青.乌梅败酱方治疗慢性非特异性溃疡性结肠炎56例[J].陕西中医,2004,25(9):797
[25]沈红.肠康液大肠水疗系统给药治疗溃疡性结肠炎30例[J].浙江中医杂志,2005,(4):158
[26]吴元祥,陈飞,薛建华,等.黄桂灌肠剂治疗溃疡性结肠炎47例[J].中国中西医结合杂志,2005,25(1):83
[27]刘安祥.结肠汤加云南白药保留灌肠治疗溃疡性结肠炎36例[J].中西医结合杂志,2004,24(11):1037
[28]陈雪清,陈小华,高记华.三黄汤加减保留灌肠治疗溃疡性结肠炎76例[J].中华实用中西医杂志,2004,4(17):990
[29]曹友平.综合疗法治疗慢性非特异性溃疡性结肠炎43例[J].新中医,2005,37(3):70
[30]张利民.愈肠胶囊治疗慢性溃疡性结肠炎112例报告[J].山东医药,2004,44(19)54
[31]张广业,邢继霞,党传玲.辨证论治配合灌肠治疗慢性溃疡性结肠炎67例[J].新中医,2005,37(2):69
[32]周继鹏,刘少琼,张楚君.乌白汤口服加灌肠治疗溃疡性结肠炎90例[J].四川中医,2005,23(3):38
[33]李向辉,毛秉豫,韩珂.溃疡性结肠炎的中医辩证分型综合治疗[J].中华实用中西医杂志,2004,4(17):355
[34]范恒,邱明义,梅家俊,等.乌梅丸对溃疡性结肠炎大鼠组织细胞因子的干预效应[J].中国临床康复,2006,10(7):87-89.
[35]姚茹冰,邱明义,胡兵,等.乌梅丸对溃疡性结肠炎大鼠结肠黏膜形态学的影响[J].广州中医药大学学报,2003,20(1):59-62.
[36]张云程.加味乌梅丸治疗溃疡性结肠炎[J].中医药研究,2000,16(6):33-34.
[37]陈亚兵,陈一峰.乌梅丸治疗溃疡性结肠炎46例[J].浙江中医药杂志,2005,428.
[38]王晓平.乌梅丸加减治疗溃疡性结肠炎28例[J].中国民间疗法,2002,10(11):52-53
[1]柯琴.伤寒来苏集·伤寒附翼.上海:上海科学技术出版社,1959.65
[2]叶天士.临证指南医案.上海:上海科学技术出版社,1991.468
[3]高学山.伤寒尚论辨似.上海:新医书局,1953.186
[4]何丰华,武维屏,李维娜.乌梅丸证治发挥。中国中医急症,2004,13(11):751-752.
[5]叶建红.对药乳香没药的药理作用与临床应用体会.安徽中医临床杂志,2003,15(3):264-265.
[6]崔锐,周金云.乳香化学和药理的研究进展.中国药学杂志,2003,38(6):407-410.
[7]万文珠,娄红祥.没药的化学成分和药理作用.国外医药·植物药分册,2005,20(6):236-241.
[8]韩捷 溃疡性结肠炎病因及中医研究进展[J].中医药信息,2002,19(5):4-6
[9]高文艳,王长洪.血瘀在溃疡性结肠炎发病机制中的研究现状.中国中西医结合消化杂志,2006,14(1):63-65.
[10]张理,黄发盛.宏观与微观结合论治溃疡性结肠炎血瘀证.光明中医,2004,19(4):21-23.
[11]吕永慧,钟东江.溃疡性结肠炎患者血液流变学与中医辨证关系.世界华人消化杂志.2001,9(8):977-978.
[1]Morris GP,Beck PL,Herridge MS,et al.Hapten induced model of chronic inflammation and ulceration in the rat colon[J].Gastroenterology,1989,96(3):795-803.
[2]Hideyuki Tozaki,Yakuya Fujita,et al.Colon-specific delivery ofR68070,a new thromboxane synthase inhibitor,using chitosan capsules:Therapeutic effects against 2,4,6-trinitr obenzene sulfonic acid-induced ulcerative colitis in rats[J].Life Sci,1999,64(13):1155-1162
[3]Hideyuki Tozaki,Tomokazu Odoriba,et al.Chitosan capsules for colon-specific drug delivery:enhanced localization of 5-aminosalicylic acid in the large intestine accelerates healing of TNBS-induced colitis in rats[J].Control Release,2002,82(1):51-61.
[4]曹永兵,张军东,阎澜,等.肠炎冲剂对溃疡性结肠炎模型大鼠的治疗作用[J].药学服务与研究,2004,4(2):114-116.
[5]Kazunori Fujino,Yoji Takami,Sebastian G,et al.Inhibition of the vanilloid receptor subtype-1 attenuates TNBS-colitis[J].Gastrointest Surg,2004,8(7):842-848.
[6]D'Argenio G,Farrace MG,Cosenza V,et al.Expression of apoptosis-related proteins in rat with induced colitis[J].Int J Colorectal Dis,2004,19(5):451-460.
[7]Cao YB,Zhang JD,Diao YY,et al.Effects of changtai granules,a traditional compound Chinese medicine,on chronic trinitrobenzene sulfonic acid-induced colitis in rats[J].World J Gastroenterol,2005,11(23):3539-3543.
[8]Jiang H,Deng CS,Zhang M,Xia J.Curcumin-attenuated trinitrobenzene sulphonic acid induces chronic colitis by inhibiting expression of cyclooxygenase-2[J].World J Gastroenterol,2006,12(24):3848-3853.
[9]Murano M,Maemura K,Hirata I,et al.Therapeutic effect of intracolonically administered nuclear factor kappa B(p65)antisense oligonucleotide on mouse dextran sulphate sodium(DSS)-induced colitis[J].Clinical and Experimental Immunology,2000,120(1):51-58.
[10]黄超,邓长生.大鼠溃疡性结肠炎模型肠组织中MIF的表达和NF-κB的激活[J].世界华人消化杂志,2006,14(6):621-625.
[11]Kunin S,Gallily R.Recognition and lysis of altered-self cells by macrophages I.Modification of target cells by 2,4,6-trinitrobenzene sulphonic acid[J].Immunology 1983,48:265-272
[12]王皓等.三硝基苯磺酸动物模型的建立[J].胃肠病学,2001;6(1):7-10
[13]王迎新,邹伟,刘成德,等.肠炎宁合剂对溃疡性结肠炎治疗作用的实验研究[J].中医药信息,2004,21(6):45-46.
[14]周静平,邓长生.罗格列酮对大鼠溃疡性结肠炎的疗效及其机制[J].临床消化病杂志,2006,18(2):84-86.
[15]张永锋,陈如山,吴正治,等.益气、活血、健脾、补肾代表方对小鼠实验性结肠炎的防治作用[J].中药药理与临床,2006,22(2):9-11.
[1]Mourelle M.Expression of Inducible Nitric Oxide Synthase Activity in Human Colon Epithelial Cell:Modulation by Tlymphocyte Derived Cytokines[J].Gut,1998,43(1):56-63.
[2]Nat hart C.Nit ric oxide as a secretory product of mammalian cells[J].FASEB J,1992,6:3051-3064.
[3]WallaceJL,Vergnolle N,Muscar MN,et al.Enhanced anti-inflammatory effects of anitric oxide releasing derivative of mesalamin in rats[J].Gastroenterology,1999,117:557-567
[4]姜恩平,孙红霞,曲娴,等.2,4,二硝基氯苯诱导的大鼠溃疡性结肠炎iNOS 表达增加[J].北华大学学报(自然科学版),2006,7(2):121-124
[5]Boughen-amith NK,Evans SM,Hawkey CJ,et al.Nitric Oxide Synthase Activity in Ulcerative Colitis and Crohn'S Disease[J].Lanet,1993,342(8866):338-340.
[1]宋巍等.生命科学[M].2001,13:82
[2]Fagerstam J P,Whiss PA,St rom M,et al.Expression ofplatelet P-selection and detection of soluble P-selection,N YP and RANTES in patient with inflammatory bowel disease[J].Inflamm Res,2000,49(9):466-472.
[3]Vainer B,Nielsen OH.Changed colonic profile of P-selectin,platelet endothelial cell adhesion molecule-1(PECAM-1),intercellularadhesion molecule-1(ICAM-1),ICAM-2,and ICAM-3 in inflammatory bowel disease[J].Clin Exp Immunol,2000,121(2):242-247.
[4]章荣华.炎症性肠病的免疫学研究进展[M].国外医学·免疫学分册,2000,23(1):57-59.
[1]费保莹.细胞粘附分子与炎症性肠病.国外医学·消化系统疾病[J].1999,19(1):15
[2]施茵,刘慧荣,龚烨靓,等.针药结合对大鼠溃疡性结肠炎TNF-α、ICAM-1基因表达的影响[J].实用中西医结合临床,2003,3(5):1-3.
[1]施茵,吴焕淦,汪崇淼,等.针药结合对溃疡性结肠炎大鼠结肠粘膜IFN-γ、IL-12表达的影响[J].针刺研究,2005,30(4):215-219
[2]许尚栋,唐福林.γ-干扰素及其在类风湿关节炎中的应用[J].新医学,1995,26(6):329
[2]梁英杰.炎症性肠病溃疡性结肠炎和克隆病[J].广东医学,2001,22(11):984-985
[3]李亚红,韩英,吴开春.炎症性肠病危险因素的流行病学调查研究[J].胃肠病学和肝病学杂志.2006,15(2):161-162
[4]艾中立,钱群.溃疡性结肠炎的发病机理及临床特点[J].大肠肛门病外科杂志,2004,10(2):92-94
[5]王丽.溃疡性结肠炎病因及中医证治浅析[J].中医药学刊,2004,2(12):2278-2279
[6]肖梅,吴正祥.炎症性肠病的病因研究进展[J].安徽医药,2005,9(12):886-889
[7]施茵,吴焕淦,汪崇淼,等.针药结合对溃疡性结肠炎大鼠结肠粘膜IFN-γ,IL-12表达的影响[J].针刺研究,2005,30(4):215-219
[8]许尚栋,唐福林.γ-干扰素及其在类风湿关节炎中的应用[J].新医学,1995,26(6):329
[9]Carol M,Lambrechts A,Van GosumA,et al.Scretion of interferon-γ,and interleukin-4 by human intrae pithelial and lamina propriagut lymphocytes[J].Gut,1998,42(5):643
[10]Tozawa K,Hanai H,Sugimoto K,e tal.Evidence for the critical role of interleukin-12 but not interferon gam ma in the pathogenesis of experimental colitis in mice[J].Gas-troente rol Hepatol,2003,18:578
[11]MacDonald TT,Monteleone G,Pender SL.Resent development in the immunology of inflammatory bowel disease[J].ScandJ Immunol,2000,51(1):2
[12]针药结合对溃疡性结肠炎大鼠结肠粘膜IFN-γ,IL-12表达的影响[J].针灸研究,2005,30(4):215-224
[13]Schurmann GM,Bishop AE,Facer Pet al[J].Gut,1995,36(7):411-418
[14]Ohtani H,Nakamura S,Watanabe Yet al.Virchows Arch[A],1992,420(5):403-409
[15]Muller WA et al[J].Exp Med,1993,178(2):449-460
[16]Misra L,Misra BB,Harris M et al[J].Gastroenterology,1993,104(3):772-779
[17]李志晋,詹丽英,马春曦,等.溃疡性结肠炎大鼠肠黏膜超微结构变化及肠组织中P-选择素表达的研究[J].广西医科大学学报,2007,24(2):183-185
[18]Fagerstam J P,Whiss PA,Strom M,et al.Expression ofplatelet P-selection and detection of soluble P-selection,N YP and RANTES in patient with inflammatory bowel disease[J].Inflamm Res,2000,49(9):466-472.
[19]Vainer B,Nielsen OH.Changed colonic profile of P-selectin,platelet endothelial cell adhesion molecule-1(PEICAM-1),intercellular adhesi molecule-1(ICAM-1),ICAM-2,and ICAM-3 in inflammatory bowel disease[J].Clin Exp Immunol,2000,121(2):242-247.
[20]章荣华.炎症性肠病的免疫学研究进展[M].国外医学·免疫学分册,2000,23(1):57-59
[21]Mcever RP.In:Beckerle Me.Cell Adhesion[M],Oxford:Oxford University Press,2001,30
[22]周同,汤雪明.医学细胞生物学[M].北京:科学出版社,2004,226
[23]宋巍等.生命科学[M],2001,13:82
[24]SethR,Raymond FD,Makgoba MW.Circulating ICAM-1 isoforms:diagnostic prospects for inflammatory and immune disorders[J].Lancet,1991,338:83-89
[25]闫萍,乐进秋,江汉.细胞黏附分子ICAM-1在慢性牙周炎牙龈组织中白细胞的表达[J].广东牙病防治,2003,11(1):18-19.
[26]施茵,刘慧荣,龚烨靓,等,针药结合对大鼠溃疡性结肠炎TNF-α、ICAM-1基因表达的影响[J].实用中西医结合临床,2003,3(5):1-3.
[27]牛凤丽,郑萍,刘文忠,等.葡聚糖硫酸钠诱导大鼠结肠炎发病机制的研究[J].胃肠病学,2003,8(5):283-286.
[28]Bendjelloul F,Rossmann P,Maly P,et al.Detection of ICAM-1 deficient and wild type mice:animmunohistochemicalstudy[J].Histochem J,2000,32:703-709.
[29]Bendi jelloulF,Maly P,Mandys V,et al.Intercellular adhesion molecule-1(ICAM-1)deficiency protects mice against severe forms of experimentally induced colitis[J].Clin Explmmunol,2000,119:57-63.
[30]MaliziaG,CalabreseA,Cottone Metal[J].Gastroenterology,1991,100(1):150-156
[31]Pooley N,Ghosh L,Sharon P.Dig Dis Sci,1995,40(1):219-225
[32]Nielsen OH,Brynskov J,Vainer B,Dig Dis Sci,1996,41(9):1780-1785
[33]TaniguchiT.Effects of the anti-ICAM-1 monoclonal antibody on dextran sodium salphat e-induced colitis in rats[J].Gastroenterol Hepatol,1998,13(9):945-949
[34]Heuschkel RB.New immunologic treatments for inflammatory bowel disease[J].Curr Opin Gastroenterol,2000,16:565-570
[35]Wallace JL,Vergnolle N,Muscar MN,et al.Enhanced anti-inflammatory effects of anitric oxide releasing derivative of mesalamin in rats[J].Gastroenterology,1999,117:557-567
[36]姜恩平,孙红霞,曲娴,等.2,4,二硝基氯苯诱导的大鼠溃疡性结肠炎iNOS表达增加[J].北华大学学报(自然科学版),2006,7(2):121-124
[37]Boughen-amith NK,Evans SM,Hawkey CJ,et al.Nitric Oxide Synthase Activity in Ulcerative Colitis and Crohn' S Disease[J].Lanet,1993,342(86):338-340.
[38]Mourelle M.Expression of Inducible Nitric Oxide Synthase Activity in Human Colon Epithelial Ceil:Modulation by Tlymphocyte Derived Cytokines[J].Gut,1998,43(1):56-63.
[39]Dikopoulos N,Nussler AK,Liptay S,et al.Inhibition of nitric oxide synthesis by aminoguanidine increases intestinal damage in the acute phase of rat TNBS-colitis[J].Eur J Olin Invest,2001,31(3):234-239.
[40]Salas A,Gironella M,Salas A,et al.Nitric oxide supplementation ameliorates dextransulfate sodium-induced colitis in mice[J].Lab Invest,2002,82(5):597-607.
[41]Takahashi A,Tomomasa T,Kaneko H,et al.Intestinal motility in an in vivo rat model of intestinal ischemia-reperfusion with special reference to the effects of nitric oxide on the motility changes[J].Pediatr Gastroenterol Nutr,2001,33(3):283-288.
[42]Potoka DA,Nadler EP,Upperman JS,et al.Role of nitric oxide and peroxynitrite in gut barrier failure[J].World J Surg,2002,26(7):806-811.
[43]Cross RK,Wilson KT.Nitric oxide in inflammatory bowel disease[J].Inflamm Bowel Dis,2003,9(3):179-189.
[44]Rumi G,Tsubouchi R,Nishio H,et al.Dual role of endogenous nitric oxide indevelopment of dextran sodium sulfate-induced colitis in rats[J].Physiol Pharmacol,2004,55(4):823-836
[45]白爱平,沈志祥.一氧化氮与结肠炎模型急性期损伤[J].世界华人消化杂志,19997(10):900-901
[46]OudferF P,Bouma G,Visser TT,et al.Serum nitrate level in ulcerative colitis and Crohr disease[J].Scand J Gastroenterol,1995;30:784-788
[47]McCafferty DM,Mudgett JS,Swain MG,et al.Inducible nitric oxide synthase plays a critical role in resolving intestinal inflammation[J].Gastroenterology,1997,112(3):1022-1027
[48]Mc Cafferty DM,et al.Roie of Inducible nitric oxide synthase in trinitrobenzene sulph -onic acid induced colitis in mice[J].Gut,1999,45(6):864-873
[49]Ueyama H,et al[J].Gut,1998,43(1):48-55
[50]郑萍,陈胜良,莫剑忠,等.炎症性肠病患者T淋巴细胞亚群的改变及临床意义[J].胃肠病学,2000,5(4):221
[51]刑同京,章廉.Th类细胞极化群体的基础与临床[M].北京:军事医学科学技术出版社.2002:61
[52]余保平,王伟岸.消化系统疾病免疫学[M].北京:科学出版社.2000:189
[53]张涛.清肠栓对UC模型大鼠结肠黏膜固有层淋巴细胞Fas、FasL蛋白表达的影响[J],江苏中医药,2007,39(8):74-76.
[54]中华医学会消化病学分会.对炎症性肠病诊断治疗规范的建议2000年[J].现代实用医学,2003,15(10):656-659
[55]Hirohata S,Ohshima N,Yanagida T,et al.Regulation of human B cell function by sulfasalazine and its metabolites[J].Int Immunopharm acol,2002,2(5):631-641
[56]王雪梅,刘玉兰.环胞菌素A治疗溃疡性结肠炎的临床分析[J].中国内镜杂志,2003,9(11):16-17.
[1]李胜志,王大敏,李冀.中医对溃疡性结肠炎UC认识探源[J].中医药学刊,2003,21(9):1450-1451
[2]张苏颖,李淑云.溃疡性结肠炎中医辨治浅析[J].山东中医杂志,2003,22(10):579-581
[3]谭丹.溃疡性结肠炎的辨证分型治疗浅析[J].中医药学刊,2001,19(6):555
[4]周丽英,王长禄.辨证治疗慢性非特异性溃疡性结肠炎45例[J].国医论坛,2003,18(1):28
[5]金纯.中医对溃疡性结肠炎的认识与治疗[J].浙江中西医结合杂志,2002,12(11):688-689.
[6]张燕,刘鑫.溃疡性结肠炎的辨治思路及方法[J].安徽中医学院学报,2003,22(2):29-30
[7]白德臣,林才志,李桂贤,等.中医药治疗溃疡性结肠炎的进展[J].河南中医2005,25(10):83-85
[8]田海河.董建华教授治疗溃疡性结肠炎的经验[J].北京中医学院学报,1991,14(1):23
[9]王宝为.中药辨治非特异性溃疡性结肠炎45例[J].辽宁中医杂志,1999,26(2):66
[10]陆一春.慢性非特异型结肠炎分型论治3则[J].安徽中医学院学报,1998,(2):90
[11]赵明亮.中医药治疗慢性非特异性溃疡性结肠炎96例临床分析[J].中医杂志1993,(5):237
[12]高亚陇,高荣进.辨证分型治疗溃疡性结肠炎50例[J].陕西中医,1998,19(3):11
[13]李万铮.辨证治疗慢性结肠炎体会[J].四川中医,1999,17(6):13
[14]傅南琳,黄俊友.中医药治疗溃疡性结肠炎研究进展[J].中医杂志,1999,40,8:501
[15]曹众毅,邬建平.平衡中焦法治疗溃疡性结肠炎的体会[J]。中国医药学报,2003,18(10):617
[16]李泽生.中药治疗溃疡性结肠炎271例[J].中华中西医杂志,2003,4(4):572
[17]税典奎,刘宏伟.中西医结合治疗溃疡性结肠炎的临床观察[J].临沂医学专科学校学报,2002,4(24):300-301
[18]张晓梅,肖培新.以寒热为纲辩治溃疡性结肠炎[J].陕西中医函授,1998,6:7-8
[19]张传儒.调肝理脾法治疗慢性非特异性结肠炎30例报告[J].中医杂志,1990,31(8):36-37
[20]田凤鸣,刘玺珍.中医药治疗慢性非特异性溃疡性结肠炎的近况[J].北京中医杂志,1984,4:38-40.
[21]白丽萍,刘西峰.当归和血汤治疗溃疡性结肠炎30例[J].陕西中医,2004,25(9):796
[22]陈良金.健脾清肠汤治疗慢性溃疡性结肠炎62例[J].四川中医,2004,22(10):57
[23]卞耀臣,李振武.温里化痰法治疗慢性溃疡性结肠炎60例[J].山东中医杂志,2004,23(8):472
[24]张磊,李利霞,王梅青.乌梅败酱方治疗慢性非特异性溃疡性结肠炎56例[J].陕西中医,2004,25(9):797
[25]沈红.肠康液大肠水疗系统给药治疗溃疡性结肠炎30例[J].浙江中医杂志,2005,(4):158
[26]吴元祥,陈飞,薛建华,等.黄桂灌肠剂治疗溃疡性结肠炎47例[J].中国中西医结合杂志,2005,25(1):83
[27]刘安祥.结肠汤加云南白药保留灌肠治疗溃疡性结肠炎36例[J].中西医结合杂志,2004,24(11):1037
[28]陈雪清,陈小华,高记华.三黄汤加减保留灌肠治疗溃疡性结肠炎76例[J].中华实用中西医杂志,2004,4(17):990
[29]曹友平.综合疗法治疗慢性非特异性溃疡性结肠炎43例[J].新中医,2005,37(3):70
[30]张利民.愈肠胶囊治疗慢性溃疡性结肠炎112例报告[J].山东医药,2004,44(19)54
[31]张广业,邢继霞,党传玲.辨证论治配合灌肠治疗慢性溃疡性结肠炎67例[J].新中医,2005,37(2):69
[32]周继鹏,刘少琼,张楚君.乌白汤口服加灌肠治疗溃疡性结肠炎90例[J].四川中医,2005,23(3):38
[33]李向辉,毛秉豫,韩珂.溃疡性结肠炎的中医辩证分型综合治疗[J].中华实用中西医杂志,2004,4(17):355
[34]范恒,邱明义,梅家俊,等.乌梅丸对溃疡性结肠炎大鼠组织细胞因子的干预效应[J].中国临床康复,2006,10(7):87-89.
[35]姚茹冰,邱明义,胡兵,等.乌梅丸对溃疡性结肠炎大鼠结肠黏膜形态学的影响[J].广州中医药大学学报,2003,20(1):59-62.
[36]张云程.加味乌梅丸治疗溃疡性结肠炎[J].中医药研究,2000,16(6):33-34.
[37]陈亚兵,陈一峰.乌梅丸治疗溃疡性结肠炎46例[J].浙江中医药杂志,2005,428.
[38]王晓平.乌梅丸加减治疗溃疡性结肠炎28例[J].中国民间疗法,2002,10(11):52-53
[1]柯琴.伤寒来苏集·伤寒附翼.上海:上海科学技术出版社,1959.65
[2]叶天士.临证指南医案.上海:上海科学技术出版社,1991.468
[3]高学山.伤寒尚论辨似.上海:新医书局,1953.186
[4]何丰华,武维屏,李维娜.乌梅丸证治发挥。中国中医急症,2004,13(11):751-752.
[5]叶建红.对药乳香没药的药理作用与临床应用体会.安徽中医临床杂志,2003,15(3):264-265.
[6]崔锐,周金云.乳香化学和药理的研究进展.中国药学杂志,2003,38(6):407-410.
[7]万文珠,娄红祥.没药的化学成分和药理作用.国外医药·植物药分册,2005,20(6):236-241.
[8]韩捷 溃疡性结肠炎病因及中医研究进展[J].中医药信息,2002,19(5):4-6
[9]高文艳,王长洪.血瘀在溃疡性结肠炎发病机制中的研究现状.中国中西医结合消化杂志,2006,14(1):63-65.
[10]张理,黄发盛.宏观与微观结合论治溃疡性结肠炎血瘀证.光明中医,2004,19(4):21-23.
[11]吕永慧,钟东江.溃疡性结肠炎患者血液流变学与中医辨证关系.世界华人消化杂志.2001,9(8):977-978.
[1]Morris GP,Beck PL,Herridge MS,et al.Hapten induced model of chronic inflammation and ulceration in the rat colon[J].Gastroenterology,1989,96(3):795-803.
[2]Hideyuki Tozaki,Yakuya Fujita,et al.Colon-specific delivery ofR68070,a new thromboxane synthase inhibitor,using chitosan capsules:Therapeutic effects against 2,4,6-trinitr obenzene sulfonic acid-induced ulcerative colitis in rats[J].Life Sci,1999,64(13):1155-1162
[3]Hideyuki Tozaki,Tomokazu Odoriba,et al.Chitosan capsules for colon-specific drug delivery:enhanced localization of 5-aminosalicylic acid in the large intestine accelerates healing of TNBS-induced colitis in rats[J].Control Release,2002,82(1):51-61.
[4]曹永兵,张军东,阎澜,等.肠炎冲剂对溃疡性结肠炎模型大鼠的治疗作用[J].药学服务与研究,2004,4(2):114-116.
[5]Kazunori Fujino,Yoji Takami,Sebastian G,et al.Inhibition of the vanilloid receptor subtype-1 attenuates TNBS-colitis[J].Gastrointest Surg,2004,8(7):842-848.
[6]D'Argenio G,Farrace MG,Cosenza V,et al.Expression of apoptosis-related proteins in rat with induced colitis[J].Int J Colorectal Dis,2004,19(5):451-460.
[7]Cao YB,Zhang JD,Diao YY,et al.Effects of changtai granules,a traditional compound Chinese medicine,on chronic trinitrobenzene sulfonic acid-induced colitis in rats[J].World J Gastroenterol,2005,11(23):3539-3543.
[8]Jiang H,Deng CS,Zhang M,Xia J.Curcumin-attenuated trinitrobenzene sulphonic acid induces chronic colitis by inhibiting expression of cyclooxygenase-2[J].World J Gastroenterol,2006,12(24):3848-3853.
[9]Murano M,Maemura K,Hirata I,et al.Therapeutic effect of intracolonically administered nuclear factor kappa B(p65)antisense oligonucleotide on mouse dextran sulphate sodium(DSS)-induced colitis[J].Clinical and Experimental Immunology,2000,120(1):51-58.
[10]黄超,邓长生.大鼠溃疡性结肠炎模型肠组织中MIF的表达和NF-κB的激活[J].世界华人消化杂志,2006,14(6):621-625.
[11]Kunin S,Gallily R.Recognition and lysis of altered-self cells by macrophages I.Modification of target cells by 2,4,6-trinitrobenzene sulphonic acid[J].Immunology 1983,48:265-272
[12]王皓等.三硝基苯磺酸动物模型的建立[J].胃肠病学,2001;6(1):7-10
[13]王迎新,邹伟,刘成德,等.肠炎宁合剂对溃疡性结肠炎治疗作用的实验研究[J].中医药信息,2004,21(6):45-46.
[14]周静平,邓长生.罗格列酮对大鼠溃疡性结肠炎的疗效及其机制[J].临床消化病杂志,2006,18(2):84-86.
[15]张永锋,陈如山,吴正治,等.益气、活血、健脾、补肾代表方对小鼠实验性结肠炎的防治作用[J].中药药理与临床,2006,22(2):9-11.
[1]Mourelle M.Expression of Inducible Nitric Oxide Synthase Activity in Human Colon Epithelial Cell:Modulation by Tlymphocyte Derived Cytokines[J].Gut,1998,43(1):56-63.
[2]Nat hart C.Nit ric oxide as a secretory product of mammalian cells[J].FASEB J,1992,6:3051-3064.
[3]WallaceJL,Vergnolle N,Muscar MN,et al.Enhanced anti-inflammatory effects of anitric oxide releasing derivative of mesalamin in rats[J].Gastroenterology,1999,117:557-567
[4]姜恩平,孙红霞,曲娴,等.2,4,二硝基氯苯诱导的大鼠溃疡性结肠炎iNOS 表达增加[J].北华大学学报(自然科学版),2006,7(2):121-124
[5]Boughen-amith NK,Evans SM,Hawkey CJ,et al.Nitric Oxide Synthase Activity in Ulcerative Colitis and Crohn'S Disease[J].Lanet,1993,342(8866):338-340.
[1]宋巍等.生命科学[M].2001,13:82
[2]Fagerstam J P,Whiss PA,St rom M,et al.Expression ofplatelet P-selection and detection of soluble P-selection,N YP and RANTES in patient with inflammatory bowel disease[J].Inflamm Res,2000,49(9):466-472.
[3]Vainer B,Nielsen OH.Changed colonic profile of P-selectin,platelet endothelial cell adhesion molecule-1(PECAM-1),intercellularadhesion molecule-1(ICAM-1),ICAM-2,and ICAM-3 in inflammatory bowel disease[J].Clin Exp Immunol,2000,121(2):242-247.
[4]章荣华.炎症性肠病的免疫学研究进展[M].国外医学·免疫学分册,2000,23(1):57-59.
[1]费保莹.细胞粘附分子与炎症性肠病.国外医学·消化系统疾病[J].1999,19(1):15
[2]施茵,刘慧荣,龚烨靓,等.针药结合对大鼠溃疡性结肠炎TNF-α、ICAM-1基因表达的影响[J].实用中西医结合临床,2003,3(5):1-3.
[1]施茵,吴焕淦,汪崇淼,等.针药结合对溃疡性结肠炎大鼠结肠粘膜IFN-γ、IL-12表达的影响[J].针刺研究,2005,30(4):215-219
[2]许尚栋,唐福林.γ-干扰素及其在类风湿关节炎中的应用[J].新医学,1995,26(6):329